Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Solaro

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
NPJ Digital Medicine|July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical dataAshkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
JAMA Network Open|November 3, 2025
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MSShalom Haggiag, Luca Prosperini, Massimo Filippi, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
NPJ Digital Medicine|July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical dataAshkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
JAMA Network Open|November 3, 2025
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MSShalom Haggiag, Luca Prosperini, Massimo Filippi, et al.
European Journal of Neurology|January 24, 2023
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosisIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Pageof 14